Literature DB >> 15994763

Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.

Kevin Whitby1, Theodore C Pierson, Brian Geiss, Kelly Lane, Michael Engle, Yi Zhou, Robert W Doms, Michael S Diamond.   

Abstract

Previous studies have suggested that alpha-glucosidase inhibitors such as castanospermine and deoxynojirimycin inhibit dengue virus type 1 infection by disrupting the folding of the structural proteins prM and E, a step crucial to viral secretion. We extend these studies by evaluating the inhibitory activity of castanospermine against a panel of clinically important flaviviruses including all four serotypes of dengue virus, yellow fever virus, and West Nile virus. Using in vitro assays we demonstrated that infections by all serotypes of dengue virus were inhibited by castanospermine. In contrast, yellow fever virus and West Nile virus were partially and almost completely resistant to the effects of the drug, respectively. Castanospermine inhibited dengue virus infection at the level of secretion and infectivity of viral particles. Importantly, castanospermine prevented mortality in a mouse model of dengue virus infection, with doses of 10, 50, and 250 mg/kg of body weight per day being highly effective at promoting survival (P < or = 0.0001). Correspondingly, castanospermine had no adverse or protective effect on West Nile virus mortality in an analogous mouse model. Overall, our data suggest that castanospermine has a strong antiviral effect on dengue virus infection and warrants further development as a possible treatment in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994763      PMCID: PMC1168722          DOI: 10.1128/JVI.79.14.8698-8706.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.

Authors:  Sigrid Elshuber; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  J Gen Virol       Date:  2003-01       Impact factor: 3.891

2.  Two distinct size classes of immature and mature subviral particles from tick-borne encephalitis virus.

Authors:  Steven L Allison; Yizhi J Tao; Gabriel O'Riordain; Christian W Mandl; Stephen C Harrison; Franz X Heinz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  Dengue virus identification by the plaque reduction neutralization test.

Authors:  P K Russell; A Nisalak
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

4.  Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses.

Authors:  M B Crabtree; R M Kinney; B R Miller
Journal:  Arch Virol       Date:  2004-12-10       Impact factor: 2.574

5.  Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.

Authors:  Kevin Whitby; Debra Taylor; Dipa Patel; Parvin Ahmed; A Stanley Tyms
Journal:  Antivir Chem Chemother       Date:  2004-05

6.  Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence.

Authors:  E A Henchal; M K Gentry; J M McCown; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1982-07       Impact factor: 2.345

7.  Functional analysis of mosquito-borne flavivirus conserved sequence elements within 3' untranslated region of West Nile virus by use of a reporting replicon that differentiates between viral translation and RNA replication.

Authors:  Michael K Lo; Mark Tilgner; Kristen A Bernard; Pei-Yong Shi
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical.

Authors:  Sujan Shresta; Jennifer L Kyle; Heidi M Snider; Manasa Basavapatna; P Robert Beatty; Eva Harris
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 9.  Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Erin Mehlhop; Elizabeth Sitati; Michael Engle
Journal:  Viral Immunol       Date:  2003       Impact factor: 2.257

10.  Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice.

Authors:  Sujan Shresta; Jennifer L Kyle; P Robert Beatty; Eva Harris
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  94 in total

1.  Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme.

Authors:  Hillary J Stahla-Beek; Daniel G April; Bejan J Saeedi; Amanda M Hannah; Susan M Keenan; Brian J Geiss
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

2.  A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition.

Authors:  Soonjeon Youn; Hyelim Cho; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.

Authors:  Jinhong Chang; Wouter Schul; Terry D Butters; Andy Yip; Boping Liu; Anne Goh; Suresh B Lakshminarayana; Dominic Alonzi; Gabriele Reinkensmeier; Xiaoben Pan; Xiaowang Qu; Jessica M Weidner; Lijuan Wang; Wenquan Yu; Nigel Borune; Mark A Kinch; Jamie E Rayahin; Robert Moriarty; Xiaodong Xu; Pei-Yong Shi; Ju-Tao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2010-11-10       Impact factor: 5.970

5.  High-content assay to identify inhibitors of dengue virus infection.

Authors:  David Shum; Jessica L Smith; Alec J Hirsch; Bhavneet Bhinder; Constantin Radu; David A Stein; Jay A Nelson; Klaus Früh; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2010-10       Impact factor: 1.738

6.  Identification of novel target sites and an inhibitor of the dengue virus E protein.

Authors:  Ragothaman Yennamalli; Naidu Subbarao; Thorsten Kampmann; Ross P McGeary; Paul R Young; Bostjan Kobe
Journal:  J Comput Aided Mol Des       Date:  2009-02-25       Impact factor: 3.686

7.  Identification of novel small-molecule inhibitors of West Nile virus infection.

Authors:  Amine O Noueiry; Paul D Olivo; Urszula Slomczynska; Yi Zhou; Ben Buscher; Brian Geiss; Michael Engle; Robert M Roth; Kyung Min Chung; Melanie Samuel; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Dengue Virus Evolution under a Host-Targeted Antiviral.

Authors:  Emily Plummer; Michael D Buck; Marisa Sanchez; Jason A Greenbaum; Julia Turner; Rajvir Grewal; Brennan Klose; Aruna Sampath; Kelly L Warfield; Bjoern Peters; Urban Ramstedt; Sujan Shresta
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

9.  Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.

Authors:  Bharath Srinivasan; Hongyi Zhou; Sreyoshi Mitra; Jeffrey Skolnick
Journal:  Bioorg Med Chem       Date:  2016-08-13       Impact factor: 3.641

10.  The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus.

Authors:  Pulin Che; Lihua Wang; Qianjun Li
Journal:  Int J Clin Exp Med       Date:  2009-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.